JAMA Intern Med

Tirzepatide edges out semaglutide in real-world weight-loss study

July 10, 2024

Tirzepatide was associated with significantly greater weight loss than semaglutide among adults who are overweight or obese, with similar rates of GI-related adverse events between groups.

• This cohort study included 18,386 adults (mean age, 52 years; 70.5% female); of whom, 77.1% were White, 11.8% Black, 1.9% Asian, and 52% had T2DM. Mean baseline weight was 110 kg.
• For those receiving tirzepatide, hazard ratios (HRs) for achieving weight loss of ≥5%, ≥10%, and ≥15% were 1.76 (95% CI, 1.68, 1.84), 2.54 (95% CI, 2.37, 2.73), and 3.24 (95% CI, 2.91, 3.61), respectively.
• On-treatment changes in weight at 3, 6, and 12 months were larger for patients receiving tirzepatide, with differences of -2.4% (95% CI, -2.5% to -2.2%), -4.3% (95% CI, -4.7% to -4.0%), and -6.9% (95% CI, -7.9% to -5.8%), respectively.

Source:

Rodriguez PJ, et al. (2024, July 8). JAMA Intern Med. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/